Funded Projects › HORIZON
Mac4Me · Macrophage Targets for Metastatic Treatment
Immunotherapies promise to be the major break-through in the treatment of metastatic cancer, but effectiveness is limited to few cancer types. Metastatic neuroblastoma, breast and prostate cancer, affecting approximately 300,000 EU-27 inhabitants of all age groups in 2020, respond not or very poorly to current immunotherapies. To establish more effective immunotherapies, we need to better understand the specific tumour cell-immune host interactions at the metastatic site. The Mac4Me Doctoral Network adopts an innovative, multidisciplinary and cross-sectional approach, with a unique and dedicated research training programme to equip young researchers with scientific knowledge and transferable skills that are essential for today’s great demand in both academic and non-academic sectors. Mac4Me aims to understand the tumour cell-immune host interactions at the metastatic site. with an in-depth molecular and mechanistic understanding of the immune and matrix changes induced by tumour cells. We will use innovative animal-free organ-on-chip systems, that recapitulate early metastasis formation of brain, bone and liver. The retrieved knowledge from the preclinical models will be integrated in data from established clinical metastases and AI machine learning algorithms will be applied to identify new immune targets. Mac4Me will align with patients and the general public from the very beginning thereby bringing societal expectations and patient needs into the centre of the project to pave the way for new standards for shared decision making and acceptable health care solutions. Mac4Me will prepare a next generation of young scientists to start their own career as independent researchers being equipped with scientific knowledge and personal skills and integrating participatory science as a starting point to address the societal demand for more effective treatment solutions for incurable metastatic disease, such as neuroblastoma, breast and prostate cancer.
Consortium · 26 organisations
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
NL · €548,741
FARON PHARMACEUTICALS OY
FI
UNIVERSIDAD POMPEU FABRA
ES · €251,971
MED'INN'PHARMA
FR
HELSINGIN YLIOPISTO
FI · €286,488
EUROPA UOMO
BE
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
IE
EUROPEAN ASSOCIATION FOR CANCER RESEARCH
UK
GENEVIA TECHNOLOGIES OY
FI · €286,488
REACT4LIFE SPA
IT · €259,438
RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG
DE · €521,078
UNIVERSITAET BERN
CH
OSLO UNIVERSITETSSYKEHUS HF
NO · €297,749
THE GARVAN INSTITUTE OF MEDICAL RESEARCH CHARITABLE INSTITUTION
AU
GRASP - Guiding Researchers & Advocates to Scientific Partnerships
US
TAMPEREEN KORKEAKOULUSAATIO SR
FI
Phialogics GmbH
DE
JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
DE
POLITECNICO DI MILANO
IT
THE UNIVERSITY OF NOTTINGHAM
UK
UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA
IT
ERASMUS UNIVERSITEIT ROTTERDAM
NL · €274,370
PEPTIMATRIX LIMITED
UK
TECHNISCHE UNIVERSITEIT DELFT
NL · €274,370
TECHNISCHE UNIVERSITAET DRESDEN
DE · €521,078
ROYAL COLLEGE OF SURGEONS IN IRELAND
IE · €572,976
Research fields
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.